MATCH Treatment Subprotocol W: Phase II Study of AZD4547 in Patients with Tumors with Aberrations in the FGFR Pathway
Description: 

This trial aims to establish whether patients with tumor mutations, amplifications or translocations in one of the genetic pathways of interest are likely to derive clinical benefit (primary objective: objective response; secondary objective: progression-free survival of at least 6 months) if treated with agents targeting that specific pathway in a single-arm design.

Study Number: 

NCG 275215 W

Phase: 
2
Principal Investigator: 
ClinicalTrials.Gov ID: 
NCT02465060

To inquire about participating in these studies, call 1-877-ASK-RPCI (1-877-275-7724) or e-mail askrpci@roswellpark.org.